Brief: Tolerance Bio Licenses Clinical-Stage Long-Acting Interleukin-7 Therapy Efineptakin Alfa From Neoimmunetech
19/08/2026 13:04
BRIEF-Tolerance Bio Licenses Clinical-Stage Long-Acting Interleukin-7 Therapy Efineptakin Alfa From Neoimmunetech Aug 19 (Reuters) - Neoimmunetech Inc 950220.KQ:
TOLERANCE BIO LICENSES CLINICAL-STAGE LONG-ACTING INTERLEUKIN-7 THERAPY EFINEPTAKIN ALFA FROM NEOIMMUNETECH TO ADVANCE PROGRAMS TARGETING THYMIC FUNCTION AND IMMUNE RESILIENCE
TOLERANCE BIO - DEAL INCLUDES POTENTIAL MILESTONE PAYMENTS UP TO $260 MILLION AND TIERED ROYALTIES
TOLERANCE BIO: PREPARING TO ADVANCE EFINEPTAKIN ALFA INTO PHASE 2 STUDIES
Source text: ID:nBw7qG3FNa
Further company coverage: 950220.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neoimmunetech
See all newsBrief: Tolerance Bio Licenses Clinical-Stage Long-Acting Interleukin-7 Therapy Efineptakin Alfa From Neoimmunetech
Brief: Emmaus Life Sciences Enters License And Distribution Agreement With Neoimmunetech
Brief: Neoimmunetech To Conduct Capital Increase Of 65 Billion Won For Operational Funds
Brief: FDA Grants Orphan Drug Designation Status To NeoImmuneTech's NT-I7 For Advanced Pancreatic Cancer Treatment
Brief: FDA Grants Orphan Drug Tag to NeoImmuneTech's Acute Radiation Syndrome Treatment